Delving into the Latest Updates on Beijing Anjianxi Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Digestive System Disorders

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1

Ia 期剂量递增阶段：主要目的：1. 评价R01治疗晚期实体瘤患者的耐受性和安全性，探索限制性毒性反应剂量以及最大耐受剂量。次要目的：1.评价R01治疗晚期实体瘤患者的药代动力学特征；2.评价R01治疗晚期实体瘤患者的初步疗效，探索Ib期临床试验推荐剂量和给药方式 Ib 期剂量扩展阶段：主要目的：1. 评价R01不同起效剂量及给药方式治疗晚期实体瘤患者的安全性。次要目的：1 进一步评价R01治疗晚期实体瘤患者的药代动力学特征；2.评价R01治疗晚期实体瘤患者的初步疗效，确定II期临床试验推荐剂量和给药方式。

[Translation]

Phase Ia dose escalation phase: Main purpose: 1. Evaluate the tolerability and safety of R01 in the treatment of patients with advanced solid tumors, and explore the limiting toxicity dose and the maximum tolerated dose. Secondary purpose: 1. Evaluate the pharmacokinetic characteristics of R01 in the treatment of patients with advanced solid tumors; 2. Evaluate the preliminary efficacy of R01 in the treatment of patients with advanced solid tumors, and explore the recommended dose and administration method for Phase Ib clinical trials Phase Ib dose expansion phase: Main purpose: 1. Evaluate the safety of R01 in the treatment of patients with advanced solid tumors at different effective doses and administration methods. Secondary purpose: 1 Further evaluate the pharmacokinetic characteristics of R01 in the treatment of patients with advanced solid tumors; 2. Evaluate the preliminary efficacy of R01 in the treatment of patients with advanced solid tumors, and determine the recommended dose and administration method for Phase II clinical trials.

Start Date12 Dec 2022

Sponsor / Collaborator

Beijing Anjianxi Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Beijing Anjianxi Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Anjianxi Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Anjianxi Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Anjianxi Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data